Company Profile
Medicenna Therapeutics Corp. Stock Price, News & Analysis
- Ticker:
- MDNA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Why the stock is moving
Current closing-price context is not available for MDNA.
Company overview
IL-2 Superkine Platform
Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology.
MDNA11
MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being evaluated alone and with pembrolizumab across solid tumors, including new cohorts in non-small cell lung and colorectal cancers.
Neoadjuvant Melanoma
The investigator-sponsored NEO-CYT study evaluates MDNA11 with nivolumab, with or without ipilimumab, before surgery for melanoma. This setting tests whether IL-2 pathway stimulation can deepen pathologic responses while the tumor remains present.
MDNA113
MDNA113 is a bifunctional anti-PD-1 and IL-2 Superkine advancing through IND-enabling studies. It is designed to combine checkpoint targeting with localized cytokine activity in one molecule.
Bizaxofusp
Bizaxofusp, formerly MDNA55, is a Phase 3-ready targeted fusion toxin for recurrent glioblastoma. Medicenna is seeking a strategic partner to advance the program into registrational development.
Future catalysts
Start of NEO-CYT enrollment planned in the first half of 2026, with interim melanoma data expected in the second half.
Updated ABILITY-1 data expected in the second half of 2026.
Completion of ABILITY-1 expansion enrollment and an end-of-Phase 1 FDA meeting to define potential registrational trials.
MDNA113 IND submission and first-in-human trial initiation planned in the second half of 2026.
Recent news
- 01
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
Source: Medicenna Therapeutics Corp.
- 02
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
Source: Medicenna Therapeutics Corp.
- 03
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Source: Medicenna Therapeutics Corp.
- 04
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Source: Medicenna Therapeutics Corp.
- 05
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Source: Medicenna Therapeutics Corp.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Medicenna Therapeutics Corp. do?
IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being evaluated alone and with...
On which exchange is MDNA stock listed?
Medicenna Therapeutics Corp. (MDNA) is associated with NASDAQ, Canada, Biopharma.
What is IL-2?
IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity.
Which conditions is Medicenna Therapeutics Corp. targeting with IL-2?
Medicenna Therapeutics Corp. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Medicenna Therapeutics Corp. describe recent progress with IL-2?
Start of NEO-CYT enrollment planned in the first half of 2026, with interim melanoma data expected in the second half. Updated ABILITY-1 data expected in the second half of 2026. Completion of ABILITY-1 expansion enrollment and an end-of-Phase 1 FDA meeting to define potential registrational trials. MDNA113 IND submission and first-in-human trial initiation...
What is ABILITY-1?
MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study.
What should investors watch for with ABILITY-1?
Updated ABILITY-1 data expected in the second half of 2026.
What is NEO-CYT?
Neoadjuvant Melanoma The investigator-sponsored NEO-CYT study evaluates MDNA11 with nivolumab, with or without ipilimumab, before surgery for melanoma.